Shopping Cart 0
Cart Subtotal
USD 0

Global Cancer Diagnostics market and Drivers, Restraints, and Opportunities 2018-2024

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2750

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 3500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 4500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Global Cancer Diagnostics Market-Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018-2024

Overview: Cancer diagnostic testing involves tests and procedures that confirms the presence of disease and identify the correct tumor type, location, extent and stage which will help physician to give the appropriate treatment. Biopsy, imaging tests, nuclear medicine scans, tumor biomarker tests are some of the diagnostic tests used for cancer diagnostics. According to the estimation of National cancer institute, in US around 1.6 million new cases of cancer are diagnosed, and 595,690 people have died due to cancer in 2016. Canada has estimated 202,400 new cases of cancer and nearly 78,000 deaths according to Canadian cancer society in 2016. While in Europe, 1.3 million people were diagnosed in 2015. According to National cancer institute, nearly 60% new cases of cancer are from Asia, Africa, Central and South American countries and nearly 70% of cancer deaths are also from this region. China has witnessed 4.3 million new cases of cancer and 2.8 million deaths in 2015. According to Indian council for medical research, India accounts for 1.4 million new cases of cancer and 736,000 cancer related death in 2016.

The cancer diagnostics market is booming due to increasing incidence of cancer globally, growing elderly population across the globe, increased use of personalized medicine in clinical practice, and development of new novel technologies such as nanotechnology. However, lack of skilled labors and high cost of diagnosis are some of the factors hampering the market growth to an extent.

Market Analysis: The Global Cancer Diagnostics Market is estimated to witness a CAGR of 11.6% during the forecast period 2018-2024. The market is analyzed based on four segments-method of diagnosis, application, end-user and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The North America is set to be the leading region for the cancer diagnostics market growth followed by Europe, Asia Pacific and Rest of the World.

Method of diagnosis Analysis: The global Cancer Diagnostics market by method of diagnosis is segmented into tumor biomarker tests, tissue diagnostics (biopsy), liquid biopsy, imaging, and others. Imaging occupied the largest share in 2017, and liquid biopsy is expected to grow at a high CAGR in the coming years due to high preference of molecular based non-invasive tests, and increasing adoption of personalized medicine. Imaging is further segmented into magnetic resonance imaging, computed tomography, ultrasound, mammography, and nuclear imaging.

Application Analysis: The global cancer diagnostics market by application is segmented into lung cancer, breast cancer, Colorectal cancer, prostate cancer and others. Lung cancer occupied the largest share in 2017, and breast cancer application is expected to be fastest growing segment during the forecasted period.

End-Users Analysis: The global cancer diagnostics market by end-users is segmented into Hospitals, diagnostic laboratories, academic & research institutes and others. Hospitals occupies a major share of cancer diagnostics market in 2017 and is expected to be same for next five years.

Key Players: F. Hoffmann-La Roche Ltd, Abbott Laboratories, Inc., Siemens Healthineers (Siemens AG), Thermo Fisher Scientific, Inc., GE Healthcare, Qiagen N.V., Agilent Technologies, Inc., Hologic, Inc., Koninklijke Philips N. V. and other predominate & niche players.

Competitive Analysis: Currently, the imaging dominates the global cancer diagnostics market. The existing leading players and other predominant market players are concentrating on this market to offer advanced products. The key market players are acquiring other companies to enhance their product portfolio and strengthen their leadership position in the market. Apart from this, key players are also launching new products to have edge in this market. For instance, in July 2017, the MEDITE Cancer Diagnostics, Inc., announced the launch of SureCyte C1 fluorogenic instant staining product universally. In April 2017, Roche announced the launch of anti-p504s (SP116) Rabbit Monoclonal Primary Antibody, for the diagnosis of prostate cancer.

Benefits: The report provides complete details about the usage and adoption rate of cancer diagnostics products in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, government initiatives toward the product adoption in the upcoming years along with the details of commercial products available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

 

 

READ MORE

Table Of Content

Scope

Table of Contents

1 INDUSTRY OUTLOOK 9

1.1 Industry overview 9

1.2 Total addressable market 9

1.3 Industry Trends 10

2 Report Outline 11

2.1 Report Scope 11

2.2 Report Summary 11

2.3 Research Methodology 12

2.4 Report Assumptions 12

3 Market Snapshot 13

3.1 Market Definition-Infoholic Research 13

3.2 Advantage of cancer diagnostics 13

3.3 Disadvantage of cancer diagnostics 13

3.4 Segmented Addressable Market (SAM) 14

3.5 Trends of the cancer diagnostics market 14

3.6 Related Markets 15

3.6.1 Companion diagnostics 15

3.6.2 Genetic testing 16

3.6.3 Point-of-Care Diagnostics 16

4 Market Outlook 16

4.1 Overview 16

4.2 Funding scenario 17

4.3 Market segmentation 19

4.4 PEST Analysis 19

4.5 Porter 5(Five) Forces 20

5 Market Characteristics 22

5.1 DRO-Global Cancer Diagnostics Market Dynamics 22

5.1.1 Drivers 22

5.1.1.1 Rising incidence of cancer globally 22

5.1.1.2 Growing geriatric population 23

5.1.1.3 Growing demand of personalized medicine 23

5.1.2 Opportunities 24

5.1.2.1 Revolutionary nanotechnology in cancer diagnostics 24

5.1.2.2 Increasing medical tourism 24

5.1.3 Restraints 25

5.1.3.1 High cost of diagnosis 25

5.1.3.2 Lack of skilled professionals 25

6 Method of Diagnosis: Market Size and Analysis 28

6.1 Overview 28

6.2 Tumor biomarker tests 29

6.3 Tissue diagnostics 31

6.4 Liquid biopsy 32

6.5 Imaging 33

6.5.1 Magnetic resonance imaging (MRI) 35

6.5.2 Computed tomography (CT) 35

6.5.3 Ultrasound 35

6.5.4 Mammography 36

6.5.5 Nuclear imaging 36

6.6 Others 36

7 Application: Market Size and Analysis 37

7.1 Overview 37

7.2 Lung cancer 38

7.3 Breast cancer 39

7.4 Colorectal cancer 39

7.5 Prostate cancer 40

7.6 Others 40

8 End Users: Market Size and Analysis 41

8.1 Overview 41

8.2 Hospitals 42

8.3 Diagnostic Laboratories 42

8.4 Academic & research institutes 42

8.5 Others 43

9 Regions: Market Size and Analysis 43

9.1 Overview 43

9.2 North America 44

9.2.1 Overview 44

9.2.2 US 45

9.2.3 Canada 46

9.3 Europe 46

9.3.1 Overview 46

9.3.2 UK 47

9.3.3 Germany 47

9.3.4 France 48

9.3.5 Spain 48

9.4 APAC 48

9.4.1 Overview 48

9.4.2 India 49

9.4.3 China 50

9.5 Rest of the World 50

10 Competitive Landscape 52

10.1 Overview 52

11 Vendor Profiles 56

11.1 F.Hoffmann-La Roche Ltd 56

11.1.1 Overview 56

11.1.2 Business Unit 59

11.1.3 Geographic Presence 60

11.1.4 61

11.1.5 Business Focus 61

11.1.6 SWOT Analysis 61

11.1.7 Business Strategy 62

11.2 Abbott Laboratories 63

11.2.1 Overview 63

11.2.2 Business Unit 69

11.2.3 Geographic Presence 69

11.2.4 Business Focus 70

11.2.5 SWOT Analysis 71

11.2.6 Business Strategy 71

11.3 Siemens Healthineers (Siemens AG) 72

11.3.1 Overview 72

11.3.2 Business Units 77

11.3.3 Geographic Presence 79

11.3.4 Business Focus 79

11.3.5 SWOT Analysis 80

11.3.6 Business Strategy 80

11.4 Thermo Fisher Scientific Inc. 81

11.4.1 Overview 81

11.4.2 Geographic Presence 87

11.4.3 Business Focus 87

11.4.4 SWOT Analysis 88

11.4.5 Business Strategies 88

11.5 GE Healthcare 89

11.5.1 Overview 89

11.5.1.1 Business unit 94

11.5.1.2 Business focus 95

11.5.1.3 SWOT analysis 95

11.5.2 Business Strategy 96

12 Companies to Watch For 97

12.1 Qiagen N.V. 97

12.1.1 Overview 97

12.2 BioMerieux S.A. 100

12.2.1 Overview 100

12.2.2 BioMerieux S.A.: Recent Developments 101

12.3 Agilent Technologies, Inc 102

12.3.1 Overview 102

12.3.2 Agilent Technologies: Recent Developments 103

12.4 Becton Dickinson and Company 105

12.4.1 Overview 105

12.4.2 Becton dickenson and company: Recent Developments 105

12.5 Hologic Inc. 106

12.5.1 Overview 106

12.5.2 Hologic Inc.: Recent Developments 106

12.6 Illumina, Inc. 108

12.6.1 Overview 108

12.6.2 Illumina Inc.: Recent Developments 109

12.7 Koninklijke Philips N.V. 112

12.7.1 Overview 112

12.7.2 Koninklijke Philips N.V.: Recent Developments 114

13 Annexure 116

13.1 Abbreviations 116

 


List Of Figure

Charts

 

CHART 1 RESEARCH METHODOLOGY OF GLOBAL CANCER DIAGNOSTICS MARKET 12

CHART 2 GLOBAL CANCER DIAGNOSTICS MARKET REVENUE, 2017-2024 (USD MILLION) 15

CHART 3 SEGMENTATION OF GLOBAL CANCER DIAGNOSTICS MARKET 19

CHART 4 PEST ANALYSIS OF GLOBAL CANCER DIAGNOSTICS MARKET 19

CHART 5 PORTER 5 FORCES ON GLOBAL CANCER DIAGNOSTICS MARKET 20

CHART 6 DRO-IMPACT ANALYSIS OF GLOBAL CANCER DIAGNOSTICS MARKET 26

CHART 7 KEY STAKEHOLDERS 26

CHART 8 GLOBAL CANCER DIAGNOSTICS MARKET BY METHOD OF DIAGNOSIS SEGMENTATION, 2017 (%) 28

CHART 9 GLOBAL CANCER DIAGNOSTICS MARKET BY METHOD OF DIAGNOSIS SEGMENTATION, 2017 (%) 28

CHART 10 GLOBAL TUMOUR BIOMARKER TESTSING MARKET FORECAST, 2017-2024 (USD MILLION) 30

CHART 11 GLOBAL TISSUE DIAGNOSTICS MARKET FORECAST, 2017-2024 (USD MILLION) 32

CHART 12 GLOBAL LIQUID BIOPSY MARKET FORECAST, 2017-2024 (USD MILLION) 33

CHART 13 GLOBAL IMAGING MARKET FORECAST, 2017-2024 (USD MILLION) 33

CHART 14 GLOBAL IMAGING MARKET BY TYPE SEGMENTATION, 2017 (%) 34

CHART 15 GLOBAL OTHERS MARKET FORECAST, 2017-2024 (USD MILLION) 37

CHART 16 GLOBAL CANCER DIAGNOSTICS MARKET BY APPLICATION SEGMENTATION, 2017 (%) 38

CHART 17 GLOBAL CANCER DIAGNOSTICS MARKET BY END-USERS SEGMENTATION, 2017 (%) 41

CHART 18 GLOBAL CANCER DIAGNOSTICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%) 44

CHART 19 CANCER DIAGNOSTICS MARKET REVENUE IN NORTH AMERICA, 2017-2024 (USD MILLION) 45

CHART 20 CANCER DIAGNOSTICS MARKET REVENUE IN EUROPE, 2017-2024 (USD MILLION) 46

CHART 21 CANCER DIAGNOSTICS REVENUE IN ASIA-PACIFIC, 2017-2024 (USD MILLION) 48

CHART 22 CANCER DIAGNOSTICS MARKET REVENUE IN REST OF THE WORLD, 2017-2024 (USD MILLION) 51

CHART 27 ABBOTT LABORATORIES: OVERVIEW SNAPSHOT 68

CHART 28 ABBOTT LABORATORIES.: BUSINESS UNITS 69

CHART 29 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE 69

CHART 30 ABBOTT LABORATORIES.: SWOT ANALYSIS 71

CHART 31 SIEMENS AG: OVERVIEW SNAPSHOT 76

CHART 32 SIEMENS AG: BUSINESS UNITS 77

CHART 33 SIEMENS AG: GEOGRAPHIC PRESENCE 79

CHART 34 SIEMENS HEALTHINEERS INC.: SWOT ANALYSIS 80

CHART 35 THERMO FISHER SCIENTIFIC INC.: OVERVIEW SNAPSHOT 84

CHART 36 THERMO FISHER SCIENTIFIC INC.: BUSINESS UNITS REVENUE 85

CHART 37 THERMO FISHER SCIENTIFIC INC.: GEOGRAPHICAL PRESENCE 87

CHART 38 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 88

CHART 39 GE HEALTHCARE: OVERVIEW SNAPSHOT 92

CHART 40 GE HELATHCARE: BUSINES UNITS 94

CHART 41 GE HEALTHACRE: GEOGRAPHY 95

CHART 42 GE HEALTHCARE: SWOT ANALYSIS 95

 

 


List Of Table

Tables

 

TABLE 1 FUNDING SCENARIO 17

TABLE 2 GLOBAL CANCER DIAGNOSTICS MARKET REVENUE BY REGIONS, 2017-2024 (USD MILLION) 44

TABLE 3 OTHER PROMINENT VENDORS OF CANCER DIAGNOSTICS MARKET 54

TABLE 4 F. HOFFMANN-LA ROCHE: OFFERINGS 56

TABLE 5 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 57

TABLE 6 ABBOTT LABORATORIES: PRODUCT OFFERINGS 63

TABLE 7 ABBOTT LABORATORIES: RECENT DEVELOPMENTS 66

TABLE 8 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS 72

TABLE 9 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS 74

TABLE 10 THERMO FISHER SCIENTIFIC INC.: PRODUCT OFFERINGS 81

TABLE 11 THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS 82

TABLE 12 GE HEALTHCARE: PRODUCT OFFERINGS 89

TABLE 13 GE HEALTHCARE: RECENT DEVELOPMENTS 90

TABLE 14 QIAGEN N.V.: SNAPSHOT 97

TABLE 15 QIAGEN N.V.: RECENT DEVELOPMENTS 97

TABLE 16 BIOMERIEUX S.A.: SNAPSHOT 100

TABLE 17 AGILENT TECHNOLOGIES: SNAPSHOT 102

TABLE 18 BECTON DICKINSON AND COMPANY: SNAPSHOT 105

TABLE 19 HOLOGIC INC.: SNAPSHOT 106

TABLE 20 ILLUMINA INC: SNAPSHOT 109

TABLE 21 KONINKLIJKE PHILIPS N.V.: SNAPSHOT 113

 

 

Licence Rights

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

F. Hoffmann-La Roche Ltd, Abbott Laboratories, Inc., Siemens Healthineers (Siemens AG), Thermo Fisher Scientific, Inc., GE Healthcare, Qiagen N.V., Agilent Technologies, Inc., Hologic, Inc., Koninklijke Philips N. V. and other predominate & niche players

Global Cancer Diagnostics Market-Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018-2024

Overview: Cancer diagnostic testing involves tests and procedures that confirms the presence of disease and identify the correct tumor type, location, extent and stage which will help physician to give the appropriate treatment. Biopsy, imaging tests, nuclear medicine scans, tumor biomarker tests are some of the diagnostic tests used for cancer diagnostics. According to the estimation of National cancer institute, in US around 1.6 million new cases of cancer are diagnosed, and 595,690 people have died due to cancer in 2016. Canada has estimated 202,400 new cases of cancer and nearly 78,000 deaths according to Canadian cancer society in 2016. While in Europe, 1.3 million people were diagnosed in 2015. According to National cancer institute, nearly 60% new cases of cancer are from Asia, Africa, Central and South American countries and nearly 70% of cancer deaths are also from this region. China has witnessed 4.3 million new cases of cancer and 2.8 million deaths in 2015. According to Indian council for medical research, India accounts for 1.4 million new cases of cancer and 736,000 cancer related death in 2016.

The cancer diagnostics market is booming due to increasing incidence of cancer globally, growing elderly population across the globe, increased use of personalized medicine in clinical practice, and development of new novel technologies such as nanotechnology. However, lack of skilled labors and high cost of diagnosis are some of the factors hampering the market growth to an extent.

Market Analysis: The Global Cancer Diagnostics Market is estimated to witness a CAGR of 11.6% during the forecast period 2018-2024. The market is analyzed based on four segments-method of diagnosis, application, end-user and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The North America is set to be the leading region for the cancer diagnostics market growth followed by Europe, Asia Pacific and Rest of the World.

Method of diagnosis Analysis: The global Cancer Diagnostics market by method of diagnosis is segmented into tumor biomarker tests, tissue diagnostics (biopsy), liquid biopsy, imaging, and others. Imaging occupied the largest share in 2017, and liquid biopsy is expected to grow at a high CAGR in the coming years due to high preference of molecular based non-invasive tests, and increasing adoption of personalized medicine. Imaging is further segmented into magnetic resonance imaging, computed tomography, ultrasound, mammography, and nuclear imaging.

Application Analysis: The global cancer diagnostics market by application is segmented into lung cancer, breast cancer, Colorectal cancer, prostate cancer and others. Lung cancer occupied the largest share in 2017, and breast cancer application is expected to be fastest growing segment during the forecasted period.

End-Users Analysis: The global cancer diagnostics market by end-users is segmented into Hospitals, diagnostic laboratories, academic & research institutes and others. Hospitals occupies a major share of cancer diagnostics market in 2017 and is expected to be same for next five years.

Key Players: F. Hoffmann-La Roche Ltd, Abbott Laboratories, Inc., Siemens Healthineers (Siemens AG), Thermo Fisher Scientific, Inc., GE Healthcare, Qiagen N.V., Agilent Technologies, Inc., Hologic, Inc., Koninklijke Philips N. V. and other predominate & niche players.

Competitive Analysis: Currently, the imaging dominates the global cancer diagnostics market. The existing leading players and other predominant market players are concentrating on this market to offer advanced products. The key market players are acquiring other companies to enhance their product portfolio and strengthen their leadership position in the market. Apart from this, key players are also launching new products to have edge in this market. For instance, in July 2017, the MEDITE Cancer Diagnostics, Inc., announced the launch of SureCyte C1 fluorogenic instant staining product universally. In April 2017, Roche announced the launch of anti-p504s (SP116) Rabbit Monoclonal Primary Antibody, for the diagnosis of prostate cancer.

Benefits: The report provides complete details about the usage and adoption rate of cancer diagnostics products in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, government initiatives toward the product adoption in the upcoming years along with the details of commercial products available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

 

 

READ MORE

Scope

Table of Contents

1 INDUSTRY OUTLOOK 9

1.1 Industry overview 9

1.2 Total addressable market 9

1.3 Industry Trends 10

2 Report Outline 11

2.1 Report Scope 11

2.2 Report Summary 11

2.3 Research Methodology 12

2.4 Report Assumptions 12

3 Market Snapshot 13

3.1 Market Definition-Infoholic Research 13

3.2 Advantage of cancer diagnostics 13

3.3 Disadvantage of cancer diagnostics 13

3.4 Segmented Addressable Market (SAM) 14

3.5 Trends of the cancer diagnostics market 14

3.6 Related Markets 15

3.6.1 Companion diagnostics 15

3.6.2 Genetic testing 16

3.6.3 Point-of-Care Diagnostics 16

4 Market Outlook 16

4.1 Overview 16

4.2 Funding scenario 17

4.3 Market segmentation 19

4.4 PEST Analysis 19

4.5 Porter 5(Five) Forces 20

5 Market Characteristics 22

5.1 DRO-Global Cancer Diagnostics Market Dynamics 22

5.1.1 Drivers 22

5.1.1.1 Rising incidence of cancer globally 22

5.1.1.2 Growing geriatric population 23

5.1.1.3 Growing demand of personalized medicine 23

5.1.2 Opportunities 24

5.1.2.1 Revolutionary nanotechnology in cancer diagnostics 24

5.1.2.2 Increasing medical tourism 24

5.1.3 Restraints 25

5.1.3.1 High cost of diagnosis 25

5.1.3.2 Lack of skilled professionals 25

6 Method of Diagnosis: Market Size and Analysis 28

6.1 Overview 28

6.2 Tumor biomarker tests 29

6.3 Tissue diagnostics 31

6.4 Liquid biopsy 32

6.5 Imaging 33

6.5.1 Magnetic resonance imaging (MRI) 35

6.5.2 Computed tomography (CT) 35

6.5.3 Ultrasound 35

6.5.4 Mammography 36

6.5.5 Nuclear imaging 36

6.6 Others 36

7 Application: Market Size and Analysis 37

7.1 Overview 37

7.2 Lung cancer 38

7.3 Breast cancer 39

7.4 Colorectal cancer 39

7.5 Prostate cancer 40

7.6 Others 40

8 End Users: Market Size and Analysis 41

8.1 Overview 41

8.2 Hospitals 42

8.3 Diagnostic Laboratories 42

8.4 Academic & research institutes 42

8.5 Others 43

9 Regions: Market Size and Analysis 43

9.1 Overview 43

9.2 North America 44

9.2.1 Overview 44

9.2.2 US 45

9.2.3 Canada 46

9.3 Europe 46

9.3.1 Overview 46

9.3.2 UK 47

9.3.3 Germany 47

9.3.4 France 48

9.3.5 Spain 48

9.4 APAC 48

9.4.1 Overview 48

9.4.2 India 49

9.4.3 China 50

9.5 Rest of the World 50

10 Competitive Landscape 52

10.1 Overview 52

11 Vendor Profiles 56

11.1 F.Hoffmann-La Roche Ltd 56

11.1.1 Overview 56

11.1.2 Business Unit 59

11.1.3 Geographic Presence 60

11.1.4 61

11.1.5 Business Focus 61

11.1.6 SWOT Analysis 61

11.1.7 Business Strategy 62

11.2 Abbott Laboratories 63

11.2.1 Overview 63

11.2.2 Business Unit 69

11.2.3 Geographic Presence 69

11.2.4 Business Focus 70

11.2.5 SWOT Analysis 71

11.2.6 Business Strategy 71

11.3 Siemens Healthineers (Siemens AG) 72

11.3.1 Overview 72

11.3.2 Business Units 77

11.3.3 Geographic Presence 79

11.3.4 Business Focus 79

11.3.5 SWOT Analysis 80

11.3.6 Business Strategy 80

11.4 Thermo Fisher Scientific Inc. 81

11.4.1 Overview 81

11.4.2 Geographic Presence 87

11.4.3 Business Focus 87

11.4.4 SWOT Analysis 88

11.4.5 Business Strategies 88

11.5 GE Healthcare 89

11.5.1 Overview 89

11.5.1.1 Business unit 94

11.5.1.2 Business focus 95

11.5.1.3 SWOT analysis 95

11.5.2 Business Strategy 96

12 Companies to Watch For 97

12.1 Qiagen N.V. 97

12.1.1 Overview 97

12.2 BioMerieux S.A. 100

12.2.1 Overview 100

12.2.2 BioMerieux S.A.: Recent Developments 101

12.3 Agilent Technologies, Inc 102

12.3.1 Overview 102

12.3.2 Agilent Technologies: Recent Developments 103

12.4 Becton Dickinson and Company 105

12.4.1 Overview 105

12.4.2 Becton dickenson and company: Recent Developments 105

12.5 Hologic Inc. 106

12.5.1 Overview 106

12.5.2 Hologic Inc.: Recent Developments 106

12.6 Illumina, Inc. 108

12.6.1 Overview 108

12.6.2 Illumina Inc.: Recent Developments 109

12.7 Koninklijke Philips N.V. 112

12.7.1 Overview 112

12.7.2 Koninklijke Philips N.V.: Recent Developments 114

13 Annexure 116

13.1 Abbreviations 116

 


List Of Figure

Charts

 

CHART 1 RESEARCH METHODOLOGY OF GLOBAL CANCER DIAGNOSTICS MARKET 12

CHART 2 GLOBAL CANCER DIAGNOSTICS MARKET REVENUE, 2017-2024 (USD MILLION) 15

CHART 3 SEGMENTATION OF GLOBAL CANCER DIAGNOSTICS MARKET 19

CHART 4 PEST ANALYSIS OF GLOBAL CANCER DIAGNOSTICS MARKET 19

CHART 5 PORTER 5 FORCES ON GLOBAL CANCER DIAGNOSTICS MARKET 20

CHART 6 DRO-IMPACT ANALYSIS OF GLOBAL CANCER DIAGNOSTICS MARKET 26

CHART 7 KEY STAKEHOLDERS 26

CHART 8 GLOBAL CANCER DIAGNOSTICS MARKET BY METHOD OF DIAGNOSIS SEGMENTATION, 2017 (%) 28

CHART 9 GLOBAL CANCER DIAGNOSTICS MARKET BY METHOD OF DIAGNOSIS SEGMENTATION, 2017 (%) 28

CHART 10 GLOBAL TUMOUR BIOMARKER TESTSING MARKET FORECAST, 2017-2024 (USD MILLION) 30

CHART 11 GLOBAL TISSUE DIAGNOSTICS MARKET FORECAST, 2017-2024 (USD MILLION) 32

CHART 12 GLOBAL LIQUID BIOPSY MARKET FORECAST, 2017-2024 (USD MILLION) 33

CHART 13 GLOBAL IMAGING MARKET FORECAST, 2017-2024 (USD MILLION) 33

CHART 14 GLOBAL IMAGING MARKET BY TYPE SEGMENTATION, 2017 (%) 34

CHART 15 GLOBAL OTHERS MARKET FORECAST, 2017-2024 (USD MILLION) 37

CHART 16 GLOBAL CANCER DIAGNOSTICS MARKET BY APPLICATION SEGMENTATION, 2017 (%) 38

CHART 17 GLOBAL CANCER DIAGNOSTICS MARKET BY END-USERS SEGMENTATION, 2017 (%) 41

CHART 18 GLOBAL CANCER DIAGNOSTICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%) 44

CHART 19 CANCER DIAGNOSTICS MARKET REVENUE IN NORTH AMERICA, 2017-2024 (USD MILLION) 45

CHART 20 CANCER DIAGNOSTICS MARKET REVENUE IN EUROPE, 2017-2024 (USD MILLION) 46

CHART 21 CANCER DIAGNOSTICS REVENUE IN ASIA-PACIFIC, 2017-2024 (USD MILLION) 48

CHART 22 CANCER DIAGNOSTICS MARKET REVENUE IN REST OF THE WORLD, 2017-2024 (USD MILLION) 51

CHART 27 ABBOTT LABORATORIES: OVERVIEW SNAPSHOT 68

CHART 28 ABBOTT LABORATORIES.: BUSINESS UNITS 69

CHART 29 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE 69

CHART 30 ABBOTT LABORATORIES.: SWOT ANALYSIS 71

CHART 31 SIEMENS AG: OVERVIEW SNAPSHOT 76

CHART 32 SIEMENS AG: BUSINESS UNITS 77

CHART 33 SIEMENS AG: GEOGRAPHIC PRESENCE 79

CHART 34 SIEMENS HEALTHINEERS INC.: SWOT ANALYSIS 80

CHART 35 THERMO FISHER SCIENTIFIC INC.: OVERVIEW SNAPSHOT 84

CHART 36 THERMO FISHER SCIENTIFIC INC.: BUSINESS UNITS REVENUE 85

CHART 37 THERMO FISHER SCIENTIFIC INC.: GEOGRAPHICAL PRESENCE 87

CHART 38 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 88

CHART 39 GE HEALTHCARE: OVERVIEW SNAPSHOT 92

CHART 40 GE HELATHCARE: BUSINES UNITS 94

CHART 41 GE HEALTHACRE: GEOGRAPHY 95

CHART 42 GE HEALTHCARE: SWOT ANALYSIS 95

 

 


List Of Table

Tables

 

TABLE 1 FUNDING SCENARIO 17

TABLE 2 GLOBAL CANCER DIAGNOSTICS MARKET REVENUE BY REGIONS, 2017-2024 (USD MILLION) 44

TABLE 3 OTHER PROMINENT VENDORS OF CANCER DIAGNOSTICS MARKET 54

TABLE 4 F. HOFFMANN-LA ROCHE: OFFERINGS 56

TABLE 5 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 57

TABLE 6 ABBOTT LABORATORIES: PRODUCT OFFERINGS 63

TABLE 7 ABBOTT LABORATORIES: RECENT DEVELOPMENTS 66

TABLE 8 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS 72

TABLE 9 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS 74

TABLE 10 THERMO FISHER SCIENTIFIC INC.: PRODUCT OFFERINGS 81

TABLE 11 THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS 82

TABLE 12 GE HEALTHCARE: PRODUCT OFFERINGS 89

TABLE 13 GE HEALTHCARE: RECENT DEVELOPMENTS 90

TABLE 14 QIAGEN N.V.: SNAPSHOT 97

TABLE 15 QIAGEN N.V.: RECENT DEVELOPMENTS 97

TABLE 16 BIOMERIEUX S.A.: SNAPSHOT 100

TABLE 17 AGILENT TECHNOLOGIES: SNAPSHOT 102

TABLE 18 BECTON DICKINSON AND COMPANY: SNAPSHOT 105

TABLE 19 HOLOGIC INC.: SNAPSHOT 106

TABLE 20 ILLUMINA INC: SNAPSHOT 109

TABLE 21 KONINKLIJKE PHILIPS N.V.: SNAPSHOT 113

 

 

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

F. Hoffmann-La Roche Ltd, Abbott Laboratories, Inc., Siemens Healthineers (Siemens AG), Thermo Fisher Scientific, Inc., GE Healthcare, Qiagen N.V., Agilent Technologies, Inc., Hologic, Inc., Koninklijke Philips N. V. and other predominate & niche players